natgillin/translations-raw huggingface dataset:
The composition, kit or use of claim 42, wherein the H2 receptor agonist is histamine or a pharmaceutically acceptable salt of histamine, such as histamine dihydrochloride. 
Sastav prema patentnom zahtjevu 40, naznačen time, da H2 receptor agonist jest histamin ili farmaceutski prihvatljiva sol histamina, kao što je histamin dihidroklorid.
A kit comprising a container containing an effective amount of the compound or a pharmaceutically acceptable derivative of the compound according to any one of claims 1-11, wherein the pharmaceutically acceptable derivative is selected from the group consisting of pharmaceutically acceptable salt, solvate, radio labeled, stereoisomer, enantiomer, diastereomer, other stereoisomeric form, racemic mixture, geometric isomer, and/or tautomer. 
Oprema koja sadrži posudu koja sadrži učinkovitu količinu spoja ili farmaceutski prihvatljivog derivata spoja prema bilo kojem zahtjevu od 1 do 19, naznačena time da je farmaceutski prihvatljiv derivat odabran iz skupine: farmaceutski prihvatljivih soli, slovata, radiomarkiranih derivata, stereoizomera, enantiomera, dijastereoizomera, drugih stereoizomerskih oblika, racemičnih smjesa, geometrijskih izomera i/ili tautomera.
subjecting the sample and probe to stringent hybridization conditions; and 
(b) podvrgavanje uzorka i probe strogim uvjetima hibridizacije; 1
W is -CH2-, -C(CH3)2-, -O- or carbonyl; n is 0 or 1; or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof. 
W je -CH>-, -C(CH3),-, ili karbonil; nje0ili 1; ili njegove farmaceutski prihvatljive soli ili njegovi enantiomeri ili dijastereomeri.
In the Examples which follow, which are not intended to limit, in any way, the scope of the present invention, the following abbreviations are used: EtOAc 
U primjerima koji slijede, a koji nisu zamišljeni kao ograničenje smisla predloženog izuma na bilo koji način, upotrijebljene su slijedeće kratice: EtOAc
The JNK inhibitor sequence of any of claims 1 to 3, wherein the JNK targeted transcription factor is selected from the group consisting of c-Jun, ATF2, and Elkl. 
JNK inhibicijska sekvenca prema bilo kojem zahtjevu od 1 do 3, naznačena time, da je navedeni JNK ciljani transkripcijski faktor odabran iz skupine koja se sastoji od c-Jun, ATF2 i Elkl.
The reaction mixture was heated to 100° C. under nitrogen for 1 hour. 
Reakcijsku smjesu grije se 1 sat na 100 "C u atmosferi dušika.
the film has been biaxially stretched, or wherein the elongation before break value as measured with ASTM method D882 of the film prior to stretching is less than 50%; or 
filmje istegnut dvoosno, ili ii. = vrijednost elongacije filma pri prekidu, izmjereno u skladu s postupkom ASTM D882, manja je od 50 % u odnosu na stanje filma prije rastezanja; ili
In certain embodiments the overall content of polyethylene oxide in the composition is at least about 80% (by wt). 
(2) najmanje jedno aktivno sredstvo odabrano od opioidnih analgetika; te pri čemu pripravak sadrži barem oko 80 % (težinski) polietilen oksida.
Interestingly, the sugar replacement composition has a similar freezing point depression as sucrose when it is dissolved in water. 
Zanimljivo, sastavina koja zamjenjuje šećer pokazala je nakon otapanja u vodi slično sniženje ledišta kao i saharoza.
As shown in FIG. 3, a locking groove 304 may be provided adjacent to the switch 302 . 
Kako je prikazano na Slici 3, utor 304 može biti priložen uz sklopku 302.
reacting an intermediate of formula (II) with an appropriate carboxaldehyde of formula (VI) with the formation of a compound of formula (I), wherein t is 1, herein referred to as compounds of formula (I-c), wherein the variables are as defined in claim 1; 
ROB pri čemu su varijable kako je definirano u zahtjevul; d) reakciju međuprodukta formule (II) odgovarajućim karboksaldehidom formule (VI) uz stvaranje spoja formule (I), pri čemu t je 1, ovdje se nazivaju spojevi formule (I-c), s =
Microaggregation therefore has an impact on in vivo distribution. 
Mikroagregacija zbog toga ima snažan utjecaj na distribuciju in vivo.
Said pins 81 are provided on the inner part 60 at the location adjacent to the indentations 82 on the first and second part 62, which defines the handgrips for opening the packaging. 
Navedeni klinovi 81 su predviđeni na unutarnjem dijelu 60 na mjestima koja se nalaze uz nazubljenja 82 na prvom i na drugom dijelu 62, koja nazubljenja predstavljaju onaj dio koji se zahvaća rukom radi otvaranje pakiranja.
Preferred sizes of the AB-aggregates according to the present invention are from 50 nm to 15 um, preferably from 100 nm to 10 um, especially from 200 nm to 5 um (defined by the length of the aggregates (i.e. the longest ex-tension). 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da AB-agregati imaju veličinu od 50 nm do 15 um, poželjno od 100 nm do 10 um, posebno pogodno od 200 nm do 5 um.
during step (d), the temperature is adjusted such that all of the aliphatic carboxylic acid(s) and aliphatic carboxylic acid salt(s) are molten. 
- < tijekom koraka (d), temperatura je podešena tako da su rastaljene sve alifatsko karboksilne kiseline i sve soli alifatskih karboksilnih kiselina.
Package according to claim 3, wherein the means (14) for dividing the modules is a perforation in the wrapping (3) which is arranged in a circumferential direction around the wrapping (3) of the modules (6; 6a, 6b, 6c). 
Paket u skladu s patentnim zahtjevom 3, naznačen time, da je sredstvo za (14) dijeljenje modula perforacija u omotu (3) koja je postavljena po obodu oko omota (3) modula (6; 6a, 6b, 6c).
Furthermore, it is known to supply pressure medium, such as CO2, to containers, such as metal containers containing whipped cream or cans of beer, by means of a CO2 cartridge containing CO2 under high pressure, such as 50 bar and higher. 
Nadalje, poznata je opskrba tlačnim medijem, kao što je CO», u spremnike kao što su metalni spremnici koji sadrže tučeno vrhnje ili konzerve piva, pomoću patrone CO; pod visokim pritiskom, od otprilike 50 bara ili više.
The pharmaceutical according to claim 13, wherein the TNF-a-related disease is one or more selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, systemic scleroderma, localized scleroderma, Sjogren's syndrome, polymyositis, dermatomyositis, ulcerative colitis, Crohn's disease, Behcet's disease, multiple sclerosis, arteriosclerosis, myasthenia gravis, ankylosing spondylitis, diabetes, arteriosclerosis, sepsis, acute infectious diseases, asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, contact dermatitis, psoriasis, acne, osteoporosis, burns, the onset of rejection associated with organs or tissue transplantation, fever, anemia, cancer, periodontal disease, glaucoma, diabetic complications, and uveitis. 
Farmaceutski pripravak prema patentnom zahtjevu 11 za upotrebu u prevenciji ili liječenju bolesti povezanih s TNF-a, naznačen time da je bolest povezana s TNF-a jedna ili više bolest iz grupe bolesti koja uključuje reumatoidni artritis, posorijatični artritis, sistemski eritemski lupus (SLE), lupus nefritis, sistemsku skelodermiju, lokalnu skelodermiju, Sjorgenov sindrom, polimiozitis, dermatomiozitis, ulcerativni kolitis, Kronovu bolest, Behcetovu bolest, multiplu sklerozu, arteriosklerozu, mijasteniju gravis, ankilozantni spondilitis, dijabetis, arteriosklerozu, sepsu, akutnu infekciju, astmu, kroničnu opstruktivnu bolest pluća (COPD), atopijski dermatitis, kontaktni dermatitis, psorijazu, akne, osteosporozu, opekline, napad ili odbacivanje povezano s transplantacijom organa ili tkiva, vrućicu, anemiju, rak, paradontozu, glaukom, dijabetičke komplikacije 1 uveitis.
FIGURE 10 is a view similar to Figure 4 of the second container embodiment showing the first assembly step; 
SLIKA 10 je pogled na spremnik sličan onome iz slike 4, koja slika prikazuje prvi korak sklapanja druge izvedbe spremnika;
A composition according to claim 9, consisting of a Ribosomal Protein Extract and a Th1-promoting adjuvant. 
Sastav za uporabu u skladu s patentnim zahtjevom 7, koji sadrži Leishmania ekstrakt ribosomskog proteina i Th-1 promovirajući adjuvans.
amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123 or with any of SEQ ID NOs: 119-133; and/or CDR2 is chosen from the group consisting of: 
(b) aminokiselinske sekvence koje imaju 4, 3, 2, ili 1 aminokiselinsku razliku s aminokiselinskom sekvencom SEQ ID NO: 123 ili s bilo kojom od SEQ ID NOs: 119-133; i/ili (ii) CDR2 se bira iz skupine koju čine:
Thus, air will be sucked into the thermoblocks 3, 4 from the hot water outlet 14. 
Tako zrak se uvlači u termoblokove 3 14 kroz izlaz za vruću vodu 14.
optionally an attractant; and 
(co) opcijski atraktant; i
An oat-based B-glucan concentrate, characterized in that its B-glucan content is 45 to 60%, and it is composed of B-glucan of the oat endosperm, protein content is 15 to 25%, starch content is less than 20%, preferably less than 10%, fat content is less than 3.0%, preferably less than 2%, and volume-average particle size is 80 to 120 µm, and at least 95% of the particles are between 20 and 500 µm, it is a light, white powder, and that it is obtained from step (d) of claim 1. 
Koncentrat B-glukana na bazi zobi, naznačen time što sadržaj B-glukana je 45 do 60%, i sastoji se od B-glukana iz endosperma zobi, sadržaj proteina je 15 do 25%, sadržaj škroba je manji od 20%, poželjno manji od 10%, sadržaj masti je manji od 3.0%, poželjno manji od 2%, i volumno-prosječna veličina čestica je 80 do 120 µm, i barem 95% čestica je između 20 i 500 µm, to je lagani, bijeli prašak, i dobiva se iz koraka (d) prema zahtjevu 1.
The compounds of the present invention can be prepared by preparation methods known in the art, by adaptation of the known processes by the skilled person or by a new process described below. 
Spojevi predloženog izuma mogu se proizvesti metodama koje su poznate u struci, prilagodbom poznatih postupaka od strane stručnjaka ili ovdje dolje opisanim novim postupkom.
Use of a pharmaceutical composition as defined in at least one of the items 1-11 for the preparation of a medicament for treating at least one metabolic syndrome and/or atherosclerosis in a patient. 
Uporaba farmaceutskog pripravka kao što je definirano u barem jednom od zahtjeva 1-11 naznačena time što je za dobivanje lijeka za liječenje dijabetesa kod pacijenta.
The compound according to any one of the preceding claims, characterized in that the pharmaceutically acceptable organic or inorganic acid is selected from the group comprising oxalic, maleic, methanesulphonic, paratoluenesulphonic, succinic, citric, tartaric, lactic, hydrochloric, phosphoric and sulphuric acid. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je farmaceutski prihvatljiva organska ili anorganska kiselina odabrana iz skupine koju čine sljedeće kiseline: oksalna, maleična, metansulfonska, paratoluensulfonska, sukcinska, limunska, tartarna, laktička, klorovodična, fosforna i sumporna,
The therapeutic composition according to claim 3 or 4, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO. 
Terapijski pripravak sukladno zahtjevu 3 ili 4, naznačen time, što polipeptid sadrži aminokiselinsku sekvencu SEQ ID NO.
The compound for use of claim 17, wherein at least a portion of the compound of claim 118 is present as a polymorphic form, wherein the polymorphic form is an amorphous form having an X-ray diffraction pattern (CuKa) with a halo peak at approximately 13.5 °2θ, substantially as shown in FIG. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 19 do 23, naznačen time što je u najmanju ruku dio spoja prisutan kao amorfni oblik s uzorkom difrakcije rendgenskih zraka (CuKa) s maksimumom hala na otprilike 13,5° 2θ, uglavnom kao što je prikazano na SL.
stripping the first urea solution with ammonia in the stripper to form a second urea solution and a first vapor phase containing ammonia, CO2 and water, 
stripiranje prve otopine uree s amonijakom u strugaču kako bi se dobila druga otopina uree i prva parna faza koja sadrži amonijak, CO2 i vodu,
Described is a process for the preparation of a compound of formula (7): wherein 
PATENTNI ZAHTJEVI 1. Postupak za dobivanje spoja formule (7): gdje
Several other sunscreen active ingredients are accepted for use in other countries, such as terephthalylidene dicamphor sulfonic acid, sold under the trademark of Mexoryl® SX, and these are also considered to be within the scope of the present invention. 
Nckoliko drugih aktivnih sastojaka za zaštitu od sunca jc prihvaćeno za upotrebu u drugim zemljama, kao što je tereftaliden dikamfor sulfonska kiselina, koja se prodaje pod zaštićenim nazivom Mexoryl* SX, i za njih se također smatra da su unutar opsega ovog izuma.
The isolated rodent cell or tissue of claim 6 or 7, wherein the cell or tissue does not express a rodent SIRPa protein. 
Izolirana stanica ili tkivo u skladu s patentnim zahtjevom 6 ili 7, naznačeni time što stanica ili tkivo ne eksprimira glodavački protein SIRPa.
The method of claim 1, wherein the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide. 
Kompleks prema zahtjevu 5, naznačen time da je biološki aktivna molekula ili kontrastno sredstvo nekovalentno vezano na peptid nosač.
A pharmaceutical composition comprising crystalline form IV of posaconazole as defined in any one of claims 1 to 6 and optionally a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da sadrži kristalni oblik IV posakonazola određen prema zahtjevu 1 ili 21 po želji farmaceutski prihvatljiv nosač.
The solution was the diluted with dichloromethane (200 mL) and washed with water (2×200 mL). 
Otopinu se zatim razrijedi diklormetanom (200 ml), te ispere s vodom (2 x 200 ml).
The Cladribine formulation for use or the use according to any of the preceding claims, wherein the pharmaceutical formulation is to be administered in combination with interferon-beta. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti u kombinaciji s interferonom-B.
The combination therapy for use according to claim 9, wherein the interferon-beta 1a is to be administered at a dose of 5 mcg to 80 mcg at one time. 
Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 9, naznačena time što interferon-B1a treba primijeniti u dozi od 5 µg do 80 µg odjednom.
In those compounds where there is an asymmetric carbon atom or an axis of chirality the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g., as racemic or diastereomeric mixtures. 
HR P20080022 T3 Spojevi u kojima postoji asimetričan ugljikov atom ili osi kiralnosti, postoje u oblicima pojedinačnih optičkih aktivnih izomera ili kao njihove smjese, npr. kao racemično ili diastereomerne smjese.
The pooling device of embodiment 18, wherein said fluid connection assembly [104] includes a first force-activated valve [182] being connected to said outlet port of said pooling device for selectively regulating a directional fluid flow of the fluid. 
Uređaj za objedinjavanje prema zahtjevu 6, naznačen time što navedeni sklop za spajanje fluida [104] sadrži prvi ventil koji se aktivira silom [182] koji je spojen na navedeni izlazni otvor navedenog uređaja za objedinjavanje radi selektivnog reguliranja usmjerenog fluidnog strujanja fluida.
The radiolabeled GRPR-antagonist as claimed in claim 1, wherein the metal chelator C is a metal chelator for technetium or rhenium. 
Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je metalni kelator C metalni kelator za tehnecij ili renij.
The compound of formula I or a pharmaceutically acceptable salt thereof may be employed in combination with other chemotherapeutic agents for the treatment of a hyperproliferative disease or disorder, including tumors, cancers, and neoplastic tissue, along with pre-malignant and non-neoplastic or non-malignant hyperproliferative disorders. 
HR P20180223 T1 PATENTNI ZAHTJEVI Spoj, naznačen time, da ima formulu Ia: ia, te se u kombinaciji s abirateronom upotrebljava u terapeutskom postupku liječenja hiperproliferativnog poremećaja, pri čemu se kod hiperproliferativnog poremećaja radi o raku prostate.
Dimethyl fumarate or monomethyl fumarate for use in treating multiple sclerosis, wherein the dimethyl fumarate or monomethyl fumarate is the only neuroprotective compound to be administered, and wherein the dimethyl fumarate or monomethyl fumarate is to be orally administered to a subject in need of treatment for multiple sclerosis at a dose of 480 mg per day. 
Dimetil fumarat ili monometil fumarat za upotrebu u liječenju multiple skleroze, naznačen time da je dimetil fumarat ili monometil fumarat jedini neuroprotektivni spoj koji se primjenjuje, i pri čemu se dimetil fumarat ili monometil fumarat oralnim putem daje osobi kojoj je potrebno liječenje multiple skleroze u dozi od 480 mg dnevno.
selecting a library member having both properties, i.target binding affinity of IC50<10-8 M, and 
(1) afinitet vezanja za cilj od Kd<10-8 M ili IC50<10-8 M, i
A use according to claim 5 wherein the proliferative disease is a solid tumor disease. 
Uporaba prema zahtjevu 4, naznačena time, da proliferativna bolest je bolest tekućeg ili čvrstog tumora.
The disintegrant is selected from the group comprising corn starch, potato starch, methylcellulose, cellulose, carboxymethylcellulose or salts thereof, such as carboxymethylcellulose calcium salt, mineral clay powders, bentonite/veegum, wetting agents such as sodium lauryl sulfate, superdisintegrants (named due to low concentration needed, i.e. 
Dezintegrant se odabire iz skupine koja sadrži kukuruzni škrob, krumpirov škrob, metilcelulozu, celulozu, karboksimetilcelulozu ili njihove soli, kao što je kalcijeva sol karboksimetilceluloze, prah mineralne gline, bentonit/v- gumu, močila kao što su natrijev lauril sulfat, superdezintegrante (nazvanih po tome što su potrebne niske koncentracije, tj.
It is activated by the plunger grip. 
On se aktivira pomoću ručice klipa.
Another aspect of the present invention is represented by the rifaximin solid preparation comprised in the pharmaceutical composition. 
Farmaceutski pripravak prema zahtjevu 7 u obliku tableta naznačen time da ima slijedeći sastav:
A method for making crystalline (±)-A9-tetrahydrocannabinol comprising: 
Postupak za dobivanje kristalnog (+)-A*-tetrahidrokanabinola naznačen time da se sastoji od:
The compound or composition for use according to claim 1, wherein the disease or disorder is a renal tumor. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak debelog crijeva.
Panel (2) for closing off an opening between two spaces, comprising a locking system (1) in order to lock the panel (2) in the event of fire, characterized in that the locking system (1) is a locking system according to one of the preceding claims. 
. za zabravljivanje (1), namijenjen zabravljivanju panela (2) u slučaju požara, naznačen time što je sustav za zabravljivanje (1) sustav za zabravljivanje u skladu s bilo kojim od prethodnih patentnih zahtjeva.
A method for producing lysine comprising fermenting the host cell of any one of claims 3 to 5. 
Transformant prema zahtjevu 3 ili 4, gdje je molekula nukleinske kiseline prema zahtjevu 1 inkorporirana u genom transformanta preko homologne rekombinacije.
Template device, as claimed in the preceding claims, characterized in that the template may be carried out with a supporting bracket (5) which is carried out as a separate piece and is provided with adjusting means such as slots (12); on the one hand, the slots (12) permit the template body to be fixed and on the other hand, the slots (12) permit the bracket to be fixed to the machine with fixing and adjusting means in which screws are utilized. 
Stroj za poliranje prema prethodnim zahljevima, naznačen time, da se šablona može izvoditi s nosivim podupiračem (5) koji se izrađuje kao zaseban komad i opskrbljen je sredstvima za podešavanje kao što su prorezi (12); pri čemu s jedne strane, prorezi (12) dozvoljavaju da se tijelo šablone učvrsti, a s druge strane, prorezi (12) dozvoljavaju podupiraču da se učvrsti na stroj pomoću sredstava za učvršćivanje i podešavanje, gdje se koriste vijci.
Heating a sample to a temperature that is below the crystal formation temperature will lead to a sample with few or none crystals with no possibility of phase transformation. 
Zagrijavanje uzorka na temperaturu koja je ispod temperature tvorbe kristala će voditi uzorku s malo ili ništa kristala koji mogu proći faznu transformaciju.
According to a seventh and an eighth aspect of the present invention, the following are provided: use of the modified FIX polypeptide in accordance with the first aspect of the present invention for preparing a drug (pharmaceutical preparation) advantageously for treating a coagulopathy; and a pharmaceutical preparation comprising the modified FIX polypeptide and, advantageously, at least one pharmaceutically acceptable excipient. 
Polipeptid za uporabu, sukladno navedenim zahtjevima 4-7, naznačen time, što je navedeni polipeptid osiguran u farmacetskom sastavu koji sadrži navedeni polipeptid i najmanje jedan farmaceutski prihvatljiv ekscipijens:; navedeni modificirani FIX polipeptid prisutan je u farmaceutskom pripravku u količini prikladnoj za primjenu u dnevnoj dozi izmedju 0.! me/kg 1 400 mg/kg tjelesne težine.
reacting a compound of formula (II): or a salt thereof, with an alkylating agent (V): 
(3) reagiranje spoja formule (II): N- CH4CHzO-€ (2 X ž ni ili njegove soli, sa sredstvom za alkilaciju (V):
The composition according to any of the preceding claims, wherein said methionine is present at a concentration of 0.01 mg/ml to 5 mg/ml. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je navedeni metionin prisutan u koncentraciji od 0.01 mg/ml do 5 mg/ml.
the XTEN sequence comprises at least 200 contiguous amino acids that exhibits at least 90% sequence identity to a comparable length of an amino acid sequence selected from the group consisting of AE912, AE288, AD576, AE576, AE624, AD836, AE864, AF864, AG864, AM875, AM923, and AM1318 as shown in Table 3; 
(a) - XTEN-sekvenca obuhvaća najmanje 200 međusobno dodirnih aminokiselina koje pokazuju najmanje 90% identiteta sekvence s usporednom duljinom aminokiselinske sekvence odabrane iz skupine koju čine AE912, AF288, AD576, AE576, AE624, AD836, AE864, AF864, AG864, AM875, AM923 i AM1318, kao što je prikazano u Tablici 3;
is hydrogen or fluorine; provided that R2 is fluorine when “ ” is no bond; 
R2 je vodik ili fluor; uz uvjet da je R> fluor kada "---- " nije veza;
The composition of claim 5, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. The composition of claim 1, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18. 
(ili) anti-CD19 scFv je kodirano sekvencom SEQ ID NO: 14; HR P20182202 T1 (iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
The method according to claim 17, wherein said flat surface is made of a material which is capable of resuming its original shape after deformation and is temperature-resistant, comprising nitrile rubber, silicone, polychloroprene or microporous expanded EVA, so as to eliminate irregularities in thickness and ensure that an inner surface of the semimanufactured component of the upper is flat during pressing. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time, da navedena ravna površina (20) izrađena je od materijala koji može ponovo zauzeti svoj početni oblik nakon deformacije (elastičan je) i otporan je na temperaturu, primjerice nitrilna guma, silikon, polikloropren ili mikroporozni ekspandirani EVA kako bi se izbjegle nepravilnosti debljine i osiguralo da unutarnja površina gornjišta (12) ostane ravna tijekom prešanja.